Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Recurrence 1Neoplasm Metastasis 1Glioma 1Astrocytoma 1

Interventions

Cyclophosphamide 27fludarabine 19Dexamethasone 18pembrolizumab 12Rituximab 12Etoposide 11venetoclax 10pomalidomide 9Gemcitabine 9Lenalidomide 8fludarabine phosphate 7daratumumab 7Bortezomib 7glofitamab 6carfilzomib 6Vincristine 6obinutuzumab 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Doxorubicin 5Cytarabine 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Carboplatin 4Azacitidine 4zanubrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × AZD1390 × 90 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡